Claims for Patent: 9,957,477

Summary for Patent: 9,957,477

Title:	Method for enzymatic treatment of tissue products
Abstract:	Methods for treating tissue matrices and tissue matrices produced according to the methods are provided. The methods can include treating a tissue matrix with a proteolytic enzyme to produce a desired pliability of the tissue matrix and/or to control the immunogenicity of the tissue matrix. The methods can also comprise performing an assay to determine if contacting the at least one collagen-containing tissue matrix with a proteolytic enzyme has altered the at least one collagen-containing tissue matrix to reduce a human immune response to the tissue matrix.
Inventor(s):	Chen; Yi (Lawrenceville, NJ), Xu; Hui (Plainsboro, NJ), Huang; Li Ting (Branchburg, NJ), Sun; Wenquan (Warrington, PA), Wan; Hua (Princeton, NJ)
Assignee:	LifeCell Corporation (Branchburg, NJ)
Application Number:	14/962,125
Patent Claims:	1. A method for treating a tissue matrix, comprising: selecting at least one collagen-containing tissue matrix; contacting the at least one collagen-containing tissue matrix with a first solution comprising a proteolytic enzyme to create an enzyme-treated tissue matrix; and treating the enzyme-treated tissue matrix with a second solution to remove at least some of the cells and cellular components from the enzyme-treated tissue matrix, wherein the enzyme comprises alcalase and is contacted with the tissue matrix under conditions sufficient to produce a desired level of pliability in the tissue matrix and to produce a desired increase in porosity of the tissue matrix and reduce an immunogenicity of the tissue matrix when implanted in a human recipient. 2. The method of claim 1, wherein the tissue matrix treatment with the second solution is performed under conditions that produce an acellular tissue matrix. 3. The method of claim 1, wherein the tissue matrix is obtained from a tissue selected from fascia, pericardial tissue, dura, umbilical cord tissue, placental tissue, cardiac valve tissue, ligament tissue, tendon tissue, arterial tissue, venous tissue, neural connective tissue, urinary bladder tissue, ureter tissue, and intestinal tissue. 4. The method of claim 1, wherein the tissue matrix is contacted with the first solution comprising the proteolytic enzyme under conditions that do not produce an undesirable change in at least one of tensile strength, tear strength, suture strength, creep resistance, burst strength, thermal transition temperature, collagenase susceptibility or combinations thereof. 5. The method of claim 1, wherein the tissue matrix is contacted with the first solution comprising the proteolytic enzyme under conditions that do not cause a statistically significant change in tensile strength, tear strength, suture strength, creep resistance, thermal transition temperature, collagenase susceptibility or combinations thereof. 6. The method of claim 1, wherein the second solution includes a detergent. 7. The method of claim 1, including removal of all the cells and cellular components from the enzyme-treated tissue matrix. 8. The method of claim 1, further comprising performing a monocyte activation assay on the enzyme-treated tissue matrix. 9. The method of claim 1, wherein the at least one collagen-containing tissue matrix includes two or more tissue matrices. 10. The method of claim 1, further comprising packaging the tissue matrix. 11. The method of claim 1, further comprising sterilizing the tissue matrix. 12. The method of claim 1, wherein the tissue matrix comprises a dermal tissue matrix. 13. The method of claim 12, wherein the dermal tissue matrix does not contain an epidermis.

Details for Patent 9,957,477

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2031-04-28